Shah, JatinShacham, SharonKauffman, MichaelDaniele, PatrickTomaras, DimitriosTremblay, GabrielCasasnovas, Rene-OlivierMaerevoet, MarieZijlstra, JoseeFollows, GeorgeP Vermaat, Joost SKalakonda, NageshGoy, Andre HenriChoquet, SylvainDen Neste, Eric VanHill, Brian TThieblemont, CatherineCavallo, Federicala Cruz, Fátima deKuruvilla, JohnHamad, NadaBouabdallah, RedaJäger, UlrichCaimi, PaoloGurion, RonitWarzocha, KrzysztofBakhshi, SameerSancho, Juan ManuelSchuster, MichaelEgyed, MiklósOffner, FritzVasilakopoulos, Theodoros PSamal, PriyankaNagy, AgnesKu, MatthewCanales Albendea, Miguel Ángel2023-02-092023-02-092021-02-02http://hdl.handle.net/10668/17083Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/EQ-5D-5LFACT-Lymdiffuse large B-cell lymphomadisutility of adverse eventshealth state utilityhealth utilityhealth-related quality of lifepatient-reported outcomesselinexorAdultAgedAged, 80 and overDrug Resistance, NeoplasmFemaleHumansHydrazinesLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPatient Reported Outcome MeasuresQuality of LifeRecurrenceTriazolesresearch article33528286open access10.2217/fon-2020-09461744-8301https://doi.org/10.2217/fon-2020-0946